Skip to content

Deep Brain Simulation Devices Market Expected to Reach USD 3.5 Billion by 2033


A recent paper published by projects that the Deep Brain Stimulation (DBS) devices market is expected to reach around $3.5 Billion by 2033, compared to the projected $1.5 Billion for 2024.

DBS systems can be used for treatment of Parkinson’s disease and other movement disorders.  They can include a device that sends electrical signals through wire electrodes implanted in the brain, similar to how a cardiac pacemaker sends electrical signals to the heart.  DBS systems interrupt the irregular signals that cause tremors and other movement symptoms when they are successfully implemented.  Doctors have used DBS systems to treat movement disorders or neuropsychiatric conditions when medications have become less effective.

According to, the growing number of neurological disorders such as Parkinsons’s disease, essential tremor, dystonia, and epilepsy, is a significant factor driving the growth of the DBS devices industry.  Furthermore, the increasing demand for minimally invasive surgical procedures augmented with growing rate of geriatric population have also been identified as some of the most crucial drivers for deep brain simulators market growth.  And while there is a global DBS devices market, North America is expected to remain the market leader with a market share exceeding 51.4% in 2023.

Recently, multiple companies have made announcements related to the DBS devices market.  For example, on January, 25, 2024, Abbott Laboratories announced that it has received FDA approval for its Liberta Rechargeable (RC) DBS system as an Implantable Pulse Generator (IPG).   According to Abbott, Liberta stands to be the world’s smallest rechargeable DBS IPG with a volume that is nearly a third smaller than other DBS devices currently available in the U.S.  Abbott also says the Liberta RC DBS system has the longest-lasting battery charge of any FDA-approved DBS system.  It can also receive and adjust therapy remotely in conjunction with Abbott’s NeuroSphere Virtual Clinic, which can allow patients to communicate with their doctors via video chat, and their doctors can adjust the neurostimulation system’s setting remotely.  Additionally, Medtronic announced just weeks ago that it secured FDA approval for its Percept™ RC DBS system, which according to Medtronic, is the thinnest dual channel neurostimulator DBS system on the market.


, , , ,

Arash Pia

Arash Pia focuses his practice on providing patent prosecution and litigation services for his clients.

Arash received his J.D. from Loyola Law School, Los Angeles while he was working full time as a Civil Engineer. At law school, he worked as a mentor for incoming law students. He also worked as a mentor for the award-winning Judge Stephen O’Neil Trial Advocacy Mentoring Program.

Arash received his Bachelor of Science in Civil Engineering from California State Polytechnic University in Pomona. He later received his Master of Science degree also in Civil Engineering from the University of Southern California’s Viterbi School of Engineering in Los Angeles. Before joining the firm, Arash worked on a variety of multi-million-dollar civil design and construction projects, including port facilities, educational buildings, and gas transmission systems. He is a licensed Professional Engineer in the State of California.

View all posts published by Arash Pia
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal